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Received September 11, 2014; accepted December 31, 2014AbstractBackground: Carbonic anhydrases (CAs), a group of metalloenzymes, are involved in numerous physiological and pathological processes such
as acidebase balance, gluconeogenesis, lipogenesis, ureagenesis, electrolyte secretion in various tissues, bone resorption and calcification, and
tumorigenicity. In the current study, we aimed to determine and compare possible alterations in the activity of carbonic anhydrase I (CA I) and
carbonic anhydrase II (CA II) isozymes by using estrogens and progestagens in female smokers and nonsmokers.
Methods: Blood samples from 30 smoker and 30 nonsmoker volunteers were drawn after obtaining informed consent. The blood samples were
centrifuged to separate the plasma and erythrocytes. Thereafter, hemolysate was prepared from the red cells. CA I and CA II were purified from
human erythrocytes with a simple one-step procedure using Sepharose 4B-l-tyrosine-sulfonamide affinity column. CAI and CA II isozymes were
treated with estrogen and progesterone-containing drugs, after which the inhibition or activation of the enzyme was determined.
Results: CA I and CA II enzyme activity was observed to be increased in female smokers. The results of this study show that dienogest is the
most effective inhibitor for human erythrocytes CA I when compared with micronized progesterone, hydroxyprogesterone caproate, estradiol
valerate, and estradiol hemihydrate in both female smokers and nonsmokers. All active ingredients have been shown to have a stronger inhibition
in smokers than nonsmokers for CA I activity. Additionally, estradiol valerate and hydroxyprogesterone caproate have stronger inhibition against
CA II enzyme activity in women who smoke.
Conclusion: The results of the current study provide important information to clinicians about how to consider the possible adverse effects of
these drugs which are produced as a result of inhibition of CA I and CA II enzyme. Clinicians should take into consideration the side effects
caused by CA I and CA II enzyme inhibition when prescribing these drugs in the treatment of different clinical conditions, especially in women
who smoke.
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Carbonic anhydrases (CAs, EC 4.2.1.1) are zinc metal-
loenzymes which reversibly catalyze the hydration of carbon
dioxide to bicarbonate and hydrogen ions, and are abundantly
presented in mammalian tissues.1 The CA reaction is involved
in many physiological and pathological processes. These
include respiration and transport of CO2 and bicarbonateociation. All rights reserved.
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trolyte secretion in various tissues and organs, biosynthetic
reactions such as gluconeogenesis, lipogenesis and urea-
genesis, bone resorption, calcification, and tumorigenicity.2,3
Because of the many CA isoenzymes involved in these pro-
cesses, CA enzyme inhibitors are used in the treatment of
some disorders including edema, glaucoma, obesity, cancer,
epilepsy, and osteoporosis.4,5
Oral contraceptives (OCs) offer safe, effective, and
reversible fertility regulation, and contain either a combi-
nation of estrogen and progestin, or only progestin. How-
ever, OCs may have some adverse effects. In some cases,
OCs have been shown to induce rare cardiovascular events
and venous thromboembolism. The estrogen component of
these drugs alters the production of liver enzymes, coagu-
lation, and fibrinolysis factors. Progestogens have various
metabolic effects apart from binding to the progesterone
receptor, also interacting with the androgen, glucocorticoid,
or mineralocorticoid receptors. Adverse effects of the pro-
gesterone component can also include altering of the lipid
metabolism negatively, fluid retention, glucose tolerance
deterioration, and an increase of peripheral insulin resis-
tance. New progestins with high specificity have been
designed to avoid interaction with other receptors and pre-
vent androgenic, estrogenic, or glucocorticoid related side
effects, and to prevent other undesirable side-effects espe-
cially on lipoproteins, clotting factors, and insulin
sensitivity.6
Cigarette smoking (CS) is the primary cause of preventable
morbidity and mortality, and abundant clinical evidence sug-
gests that CS is more harmful to women than men. CS alters
endothelial function, the redox state, inflammation, and global
DNA methylation. Cardiovascular risk factors seem to appear
earlier in young healthy female smokers than in young healthy
male smokers.7 In young women, the risk of cardiovascular
disease is very low in OC users but can be strongly influenced
by smoking and the presence of other risks factors, such as
hypertension, obesity, and diabetes mellitus, more so than for
women over 35 years of age.8
In the present study we aimed to determine and compare
possible alterations in activity of isozymes CA I and CA II
caused by the use of estrogen (estradiol valerate and estra-
diol hemihydrate) and progesterone-containing drugs
(hidroxyprogesterone caproate, micronized progesterone,
and dienogest) in female smokers and nonsmokers. CA
isoenzymes present in different tissues and consist of
metabolic wastes due to respiration diffuse through the
blood, thereby containing venous blood. Mammalian red
blood cells mainly express CA II and CA I. For this reason,
we focused on plasma CA isoenzymes I and II in this article.
The aim of this study was to determine whether these drugs
can be a risk factor for the presence of CA I and CA II
isoenzyme inhibition in smokers. Furthermore, smoking is a
risk factor for the enzyme inhibition degree of these drugs,
and side effects of the drugs can be increased by smoking.2. Methods
The necessary materials Sepharose 4B, l-tyrosine, sulfon-
amide, protein assay reagents, phenol red, and chemicals for
electrophoresis were obtained from Sigma-Aldrich Co, St.
Louis, MO, USA. All other chemicals were of analytical grade
and obtained from either Sigma or Merck (Kenilworth, NJ,
USA). Those medical drugs used in this study were provided
by the local pharmacy.2.1. Purification of CA from human erythrocytes using
affinity chromatographyThe study comprised of 30 smoker and 30 nonsmoker
women aged 18e30 years. The smoker group was chosen
from women who smoke approximately five cigarettes per
day. Informed consent was obtained from all participants, and
the study was also approved by the local Ethics Committee of
Balikesir University. Erythrocytes were purified from fresh
heparinized human blood obtained from the healthy volun-
teers. The blood samples were centrifuged at 1000g for
20 minutes, after which the plasma and buffy coat were
removed. The red cells were isolated and washed twice with
0.9 % NaCl, and hemolyzed with 1.5 volumes of ice-cold
water. The ghost and intact cells were removed by centrifu-
gation at 3100g for 30 minutes at 4C. The pH of the hemo-
lysate was adjusted to 8.7 with a solid Tris base, and applied to
the prepared Sepharose 4B-L-tyrosine-sulfonamide affinity
column equilibrated with 25 mM Tris-HCl/22 mM Na2SO4
(pH 8.7).9 The affinity gel was washed with the same buffer.
The hCA I and CA II were eluted with 0.1 M NaCH3COO/
0.5 M NaClO4 (pH 5.6). The absorbance of the protein in the
column effluents was determined spectrophotometrically at
280 nm. CO2-hydratase activity in the eluates was determined,
and the active fractions were collected. The purified enzymes
were then stored at 4C, in order to maintain activity. The
active contents of selected drugs are estradiol hemihydrate,
dienogest, estradiol valerate, micronized progesterone, and
hidroxyprogesterone caproate. The structures of active sub-
stances of the drugs are shown in Fig. 1.2.2. Total protein determinationA rate of absorbance at 280 nm was used to monitor the
protein in the column effluents. Quantitative protein determi-
nation was achieved by absorbance measurements at 595 nm
according to the method described by Bradford10 using the
bovine serum albumin standard.2.3. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis of enzymesSodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) was performed in order to verify the purified
enzyme. It was carried out in 12% and 3% acrylamide
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Fig. 1. Structures of the active substances.
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tively, containing 0.1% SDS according to the method
described by Laemmli.11 A 20 mg sample was applied to the
electrophoresis medium. Gel was stained for 1.5 hour in 0.1%
Coomassie Brilliant Blue R-250 dye (SigmadAldrich, Ger-
many) in 50% methanol and 10% acetic acid, and then
destained with several changes of the same solvent without the
dye.2.4. CA I and CA II enzyme activities assayThe CA I and CA II enzyme activities were assayed by
following the hydration of CO2 according to the methodFig. 2. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of human
carbonic anhydrase isozymes. The poled fractions from affinity chromatog-
raphy (Sepharose 4-B, L-tyrosine, sulfanilamide) was analyzed using sodium
dodecyl sulfate polyacrylamide gel electrophoresis (12% and 3%) and
revealed with Coomassie Blue staining. Experimental conditions were as
described in the Methods. Lane 1 contained 5 mg of various molecular mass
standards: b-galactosidase (116.0), bovine serum albumin (66.2), ovalbumin
(45.0), lactate dehydrogenase (35.0), restriction endonuclease (25.0), b-
lactoglobulin (18.4), and lysozyme (14.4). One-hundred microgram of purified
human carbonic anhydrase I and II (lane 2 and lane 3) migrated with a
mobility corresponding to an apparent Mr 33.0 kDa.described by Wilbur and Anderson.12 CO2-hydratase activity
of the enzyme was determined at room temperature in a
0.15 M Na2CO3/0.1 M NaHCO3 (pH 10.0) buffer using phenol
red (pH 8.6) as an indicator, and saturated carbon dioxide
concentration as substrate in a final volume of 4.2 mL. The
duration (in seconds) of the color change from red to yellow in
solution was measured in a 10-mL glass tube with 1 cm
diameter. The enzyme unit (EU) was calculated using the
equation (t0tc/tc), where t0 and tc are the times for pH
changes of the nonenzymatic and enzymatic reactions,
respectively.2.5. In vitro studies for estrogen and progesterone
containing drugsIn this study, estradiol valerate, estradiol hemihydrate,
micronized progesterone, dienogest, and hidroxyprogesterone
caproate were used as drugs. Different concentrations of the
drugs (5.13 mM; 10.26 mM; 15.38 mM; 20.51 mM; and
25.64 mM) were added to the enzyme activity determination
medium in 4.2 mL of total volume. Duration (in seconds) of
the color change from red to yellow in solution was measured
in a 10-mL glass tube with 1 cm diameter. Control cuvette
activity in the absence of inhibitor was taken as 100%. All
compounds were tested in triplicate at each concentration
used. The EU was calculated using the equation (t0-tc/tc),
where t0 and tc are the time periods for pH change of the
nonenzymatic and enzymatic reactions, respectively. For each
inhibitor, an activity%-[inhibitor] graph was drawn (Fig. 2).
3. Results
In this study, human erythrocyte CA I and CA II were
purified, with a simple one-step method, by using Sepharose
4B-Ltyrosine-sulfonamide affinity gel with the elution buffer
0.1 M NaCH3COO/0.5 M NaClO4 (pH 5.6). Purity of the
enzyme was confirmed by SDS-PAGE (Fig. 2). Inhibition or
activation effects of drugs on enzyme activity were tested
under in vitro conditions. Inhibition graphs using the drugs are
shown in Fig. 3. The overall purification gave CA in a yield of
31.74% with a specific activity of 5359.48 EU/mg proteins and
the overall purification was 259.16-fold (Table 1). IC50 values
were calculated from Activity %-[inhibitor] graphs and are
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Fig. 3. (A) Nonsmokers. (B) Smokers. hCA I ¼ human carbonic anhydrase I; hCA II ¼ human carbonic anhydrase II.
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designated as 100% activity. Dienogest has been shown to
have the strongest inhibition for CA I and CA II activities in
both smoker and nonsmoker women (Fig. 2). Specificactivities of human CA I and CA II for each group were
provided in Table 3. It was observed that CA I and CA II
enzyme activity was increased in smoker women. All active
ingredients have been shown to manifest stronger inhibition in
Table 1
Summary of the purification of human carbonic anhydrase I and II.
Step Volume (mL) Activity (U/mL) Total activity (U) Protein amount
(mg/mL)
Total protein
(mg)
Specific activity
(U/mg)
Overall
yield %
Overall purification
(fold)
Hemolysate 25 41.33 1033.25 1.9980 49.9500 20.68 100.00 d
Affinity chromatography 4 82 328 0.0153 0.0612 5359.48 31.74 259.16
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estradiol valerate and hydroxyprogesterone caproate have
stronger inhibition against CA II enzyme activity in women
smokers. Smoking has not deterioriated CA II enzyme activity
with estradiol hemihydrate, micronized progesterone, and
dienogest. Micronized progesterone has the weakest inhibitor
activity against CA I and CA II (Table 2).
4. Discussion
In the present study, the effects of the estrogen and
progesterone-containing drugs on human erythrocyte CA
enzyme activity were investigated in female smokers and
nonsmokers. There are various studies in literature about CA
enzyme inhibition. But according to our review of the litera-
ture, this is the first study that associated smoking and drugs
with enzyme inhibition. The results of the current study
revealed that human erythrocyte CA I and CA II activities
have been inhibited at different levels (Fig. 2). Dienogest was
the strongest inhibitor for human CA. However, the inhibitor
effect of micronized progesterone was found to be lower than
the other drugs.
CAs, a group of metalloenzymes, are involved in numerous
physiological and pathological processes. These are gluco-
neogenesis, lipogenesis, ureagenesis, tumorigenicity, and the
growth and virulence of various pathogens. CA enzyme in-
hibitors are used as antidiuretics and antiglaucoma drugs. In
addition to their established roles, CA inhibitors have beenTable 2
The IC50 values of drugs.
Active ingredients Nonsmokers Smokers
hCA I
IC50 mM
hCA II
IC50 mM
hCA I
IC50 mM
hCA II
IC50 mM
Progesterone 1536 1141 1174 1221
Estradiol hemihydrate 43.71 42.82 30.01 43.81
Dienogest 8.14 8.73 7.59 9.21
Estradiol valerate 32.61 41.68 29.48 37.66
Hydroxyprogesterone caproate 180.49 213.25 175.35 178.6
hCA I ¼ human carbonic anhydrase I; hCA II ¼ human carbonic anhydrase II.
Table 3
The specific activities of human carbonic anhydrase I and II for each group.
Specific activity (EU/mg)
hCA I hCA II
Nonsmokers 5.34 5.65
Smokers 6.81 6.11investigated for possible antiobesity, anticancer, and anti-
infective roles in recent years.13
Many drugs and chemicals at low dosages affect the
metabolism by changing normal enzyme activity, especially
the inhibition of specific enzymes. Estrogen and progesterone-
containing drugs are commonly used in obstetrics and gyne-
cology. OCs are used for birth control, but also have many
noncontraceptive benefits. These benefits include improved
cycle control and relief from menstrual symptoms, improved
acne and hirsutism, improved bone health, and prevention of
ovarian, endometrial, and colorectal cancer.14 Estradiol
valerate and estradiol hemihydrate are the components of OCs
or hormone replacement therapy. Estradiol valerate is a natural
estrogen and recently has been used as a component in new
oral OCs formulations.6
Dienogest is a new nonethyl progestin, and is also an
estrane. In contrast with the ethyl estranes, dienogest is anti-
androgenic and has no estrogenic and glucocorticoid activity.
It has a high endometrial efficacy, so when used in combina-
tion with ethinyl estradiol or estradiol valerate can easily
stabilize the menstrual cycle of women.15 Endometriosis is
defined as the presence of functional endometrial tissue
outside the uterus, causing diverse progressive symptoms such
as infertility, pelvic pain, and dysmenorrhea. Because of its
strong endometrial efficacy, dienogest has been used to treat
endometriosis in recent years. Dienogest has antiproliferative
and anti-inflammatory effects in the treatment of endometri-
otic lesions.16 Though it was believed that dienogest has a
minimal clinically significant effect on metabolic, lipid, and
hemostatic parameters because of its antiandrogenic activity,
we determined that dienogest has a marked inhibitory effect
on CA I and CA II.
Micronized progesterone is a natural progestagen, and is
widely used in the treatment of secondary amenorrhea, pre-
menopausal bleeding disorders, and luteal phase disorders; it
is also used for the prevention of preterm labor.17 Transdermal
estrogen and micronized progesterone may be also a choice
for hormone replacement therapy.18 Hydroxyprogesterone
caproate is a synthetic progestin and is used for preterm birth
prevention in pregnancy.19 Micronized natural progesterone
has a weak inhibitory effect on CA enzymes than hydrox-
yprogesterone caproate. Therefore it can be a first choice for
preventing preterm labor in pregnancy. Micronized proges-
terone can also be a component choice for hormone replace-
ment therapy in the postmenopausal period.
Tobacco smoke contains large numbers of organic and
inorganic compounds. A broad variety of these substances are
absorbed from inhaled cigarette smoke. Among these
numerous substances, many could be considered as a means to
518 M.I. Taskin et al. / Journal of the Chinese Medical Association 78 (2015) 513e519explain an effect on CA activity. One of the best known
constituents of cigarette smoke is nicotine. Nicotine as a res-
piratory stimulant forces CO2 elimination.
20 CA catalyses the
reversible hydration of CO2 and provides acidebase regula-
tion.1 Although Abel et al20 have reported that erythrocyte CA
activity was decreased in smokers, we found that CA I and CA
II activity were increased in women smokers. This increased
level of CA can be attributed to increased CO2 levels in
smoker women for adaptation to acute influences on the
acidebase balance. According to our results, CA enzymes,
especially CA I enzyme, were inhibited by estrogen and
progesterone-containing drugs in smoker women with lower
doses than nonsmokers. Therefore, it can be said that smoking
is a risk factor for the enzyme inhibition degree of these drugs,
and side effects of the drugs can be increased by smoking.
The effects of various drugs on human CA enzymes were
investigated in previous studies. In one particular in vitro
study, the effect of antipsychotic drugs on the CA I and CA II
isoenzymes were investigated.21 Their results showed that all
of the antipsychotic drugs inhibited CA enzyme activity.
Among such drugs, aripiprazole and pramipexole were found
to be the strongest inhibitors of CA I (IC50: 3.64 mM and
5.37 mM) and CA II (IC50: 4.16 mM and 4.81 mM) activity.
In the current study, dienogest was the strongest inhibitor.
IC50 values of dienogest were found to be 8.14 mM and
8.73 mM in nonsmokers; 7.59 mM and 9.21 mM in smokers for
CA I and CA II, respectively. Ottlecz et al22 have shown that
ampicillin sulfate inhibits human CA enzyme. The IC50 value
of this work is 385 mm for human CA I and 774 mm for human
CA II. In another study, in vitro effects of some analgesic
drugs on CA enzyme activity were evaluated. Dexketoprofen
trometamol has been shown to be the strongest inhibitor
against the erythrocyte human CA I and human CA II,
whereas diclofenac sodium increased enzyme activities.23
Gencer et al24 investigated the effects of the some
anabolic compounds on CA I and CA II enzymes, and the
report that 17-b estradiol is the strongest inhibitor against
CA I and diethylstilbestrol is the strongest inhibitor against
CA II enzyme activity. In our study, dienogest, a synthetic
new progestin, was found to be the strongest inhibitor against
both CA I and CA II enzymes. In another study, researchers
evaluated the in vivo effects of OCs on CA, paraoxonase, and
catalase enzyme activities in a mouse model; they revealed
that OCs did not change the erythrocytes CA activity.3 In the
current study we showed the enzyme alteration, but our re-
sults could be obtained with additional in vivo studies. The
previous study in mice used a microgram drug as the
designated amount, but in the current study a micromolar
drug was used. It was determined that there was an enzyme
inhibition in both studies. The earlier study was made by our
group in our laboratory. However, the drugs used in this
study are different. In the present study, instead of combined
estrogen and progesterone regimens we used pure estrogen
or progesterone. Our results contain human erythrocyte CA
enzyme alterations. This is because it is apparent that every
experimental model does not reflect human physiology
identically.There are some limitations of our study. Due to the ne-
cessity of high blood volume for each patient, the IC50 value
could not be calculated for each patient. The blood from 30
patients was used to create a pool for purifying CA. Only one
IC50 value for 30 patients was calculated in each group so
statistical analysis could not be performed. However, there are
different articles in the literature which describe the use of this
method.21e26
In conclusion, according to the authors' knowledge, this is
the first study which associated smoking and estrogen and
progesterone-containing drugs with enzyme inhibition. In this
study, dienogest was the strongest inhibitor against human CA
I and human CA II enzyme activity. All active ingredients
have been shown to have a stronger inhibition against smokers
than nonsmokers for human CA I activity. The results of the
current study gives information about how to consider the
possible adverse effects produced as a result of inhibition of
CA I and CA II enzyme inhibition when prescribing these
drugs, particularly to women who smoke.
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